Literature DB >> 11583322

Impaired platelet function among platelet donors.

P Jilma-Stohlawetz1, N Hergovich, M Homoncik, L Dzirlo, M Horvath, M Janisiw, S Panzer, B Jilma.   

Abstract

BACKGROUND: Platelet transfusions are effective for the prevention and treatment of bleeding in patients with disorders of platelet number and/or function. In recent years plateletpheresis concentrates have outnumbered pooled platelet concentrates, albeit with significant differences between nations. Thus, the platelet quality of individual donors has become increasingly important. The aim of this study was to gain an estimate for the prevalence of impaired platelet function among platelet donors. STUDY DESIGN AND METHODS: We determined the inter-donor variability in platelet plug formation with a PFA-100 analyzer, the prevalence of impaired thromboxane formation, and effects of the density in alpha2 integrin polymorphism and density.
RESULTS: (i) Collagen-epinephrine induced closure time (CEPI-CT) showed a great inter-subject variability in platelet donors and was higher than in healthy controls (p = 0.008). One-fifth of donors had abnormal CEPI-CT values and 11% exceeded >300 s (max measurable value). (ii) Decreased serum thromboxane B2 levels were found in 9% of all donors, compatible with surreptitious intake of cyclooxygenase inhibitors or with an aspirin-like defect. CEPI-CT correlated inversely with TxB2-levels in donors and controls. (iii) The density of the alpha2-integrin correlated negatively with CEPI-CT and CADP-CT values in controls, but was not responsible for the observed impaired platelet function in donors. (iv) Finally, the ABO blood group system modulates closure times.
CONCLUSION: In sum, a large number of platelet donors present with prolonged closure times. Decreased thromboxane formation and frequent platelet donation partly account for this observation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583322

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Platelet Dysfunction in Blood Donors Detected by Platelet Function Analyzer PFA-100™.

Authors:  Malika Belkacemi; Abdellah Berber
Journal:  Cureus       Date:  2022-05-30

Review 2.  Novel and unexpected clearance mechanisms for cold platelets.

Authors:  Viktoria Rumjantseva; Karin M Hoffmeister
Journal:  Transfus Apher Sci       Date:  2009-11-20       Impact factor: 1.764

3.  Clinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy.

Authors:  Susanna M Nazarian; Jason B Thompson; Tyler J Gluckman; Katherine Laws; Jayesh T Jani; Thomas S Kickler; Jeffrey J Rade
Journal:  Thromb Res       Date:  2009-06-05       Impact factor: 3.944

4.  Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial.

Authors:  Christian Schoergenhofer; Eva-Luise Hobl; Michael Schwameis; Georg Gelbenegger; Thomas Staudinger; Gottfried Heinz; Walter S Speidl; Christian Zauner; Birgit Reiter; Irene Lang; Bernd Jilma
Journal:  Eur J Clin Invest       Date:  2017-06-20       Impact factor: 4.686

5.  Platelet responses to agonists in a cohort of highly characterised platelet donors are consistent over time.

Authors:  S F Garner; A Furnell; B C Kahan; C I Jones; A Attwood; P Harrison; A M Kelly; A H Goodall; R Cardigan; W H Ouwehand
Journal:  Vox Sang       Date:  2016-12-21       Impact factor: 2.144

6.  Effect of Frequency of Platelet Apheresis on Coagulation Function in Donors: A Prospective Cohort Study.

Authors:  Qing Feng; Faming Zhu; Chunyan Li; Beijie Guo; Jun Ye; Jiangtian Chen
Journal:  Indian J Hematol Blood Transfus       Date:  2019-05-06       Impact factor: 0.900

7.  Screening platelet function in blood donors.

Authors:  Pascal Pedini; Jean-Baptiste Baudey; Katia Pouymayou; Celine Falaise; Manal Ibrahim-Kosta; Melanie Vélier; Clémence Demerle; Hajer Graiet; Catherine Dragutini; Anne-Marie Dombey; Jacques Chiaroni; Marie Christine Alessi; Christophe Picard
Journal:  Transfusion       Date:  2022-06-24       Impact factor: 3.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.